Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent.

Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Abstract Text:

Michael W Kattan,Jack Cuzick,Gabrielle Fisher,Daniel M Berney,Tim Oliver,Christopher S Foster,Henrik ,Victor Reuter,Paul Fearn,James Eastham,Peter T Scardino, ,Michael W Kattan,Jack Cuzick,Gabrielle Fisher,Daniel M Berney,Tim Oliver,Christopher S Foster,Henrik Møller,Victor Reuter,Paul Fearn,James Eastham,Peter T Scardino, ,Michael W Kattan,Jack Cuzick,Gabrielle Fisher,Daniel M Berney,Tim Oliver,Christopher S Foster,Henrik Møller,Victor Reuter,Paul Fearn,James Eastham,Peter T Scardino, ,

BACKGROUND.: The prognosis of men with clinically localized prostate cancer is highly variable, and it is difficult to counsel a man who may be considering avoiding, or delaying, aggressive therapy. After collecting data on a large cohort of men who received no initial active prostate cancer therapy, the aim was to develop, and to internally validate, a nomogram for prediction of disease-specific survival. METHODS.: Working with 6 cancer registries within England and numerous hospitals in the region, a population-based cohort of men diagnosed with prostate cancer between 1990 and 1996 was constructed. All men had baseline serum prostate-specific antigen (PSA) measurements, centralized pathologic grading, and centralized review of clinical stage assignment. Based on the clinical and pathologic data from 1911 men, a statistical model was developed and validated that served as the basis for the nomogram. The discrimination and calibration of the nomogram were assessed with use of one-third of the men, who were omitted from modeling and used as a test sample. RESULTS.: The median age of the included men was 70.4 years. The 25th and 75th percentiles of PSA were 7.3 and 32.6 ng/mL respectively, and the median was 15.4 ng/mL. Forty-two percent of the men had high-grade disease. The nomogram predicted well, with a concordance index of 0.73, and had good calibration. CONCLUSIONS.: An accurate tool was developed for predicting the probability that a man with clinically localized prostate cancer will survive his disease for 120 months if the cancer is not treated with curative intent immediately. The tool should be helpful for patient counseling and clinical trial design. Cancer 2008. (c) 2007 American Cancer Society.

Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Publishing Authors By Initials

MW Kattan,J Cuzick,G Fisher,DM Berney,T Oliver,CS Foster,H ,V Reuter,P Fearn,J Eastham,PT Scardino, ,MW Kattan,J Cuzick,G Fisher,DM Berney,T Oliver,CS Foster,H Møller,V Reuter,P Fearn,J Eastham,PT Scardino, ,MW Kattan,J Cuzick,G Fisher,DM Berney,T Oliver,CS Foster,H Møller,V Reuter,P Fearn,J Eastham,PT Scardino, ,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cancer

VOLUME: 112

Page Numbers: 69-74

Journal Abbreviation: Cancer

ISSN: 0008-543X

DAY: 1

MONTH: Jan

YEAR: 2008

Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 374236

Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent.

AFFILIATION: Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent Related Publications

• A new concept in the treatment of Peyronie's disease.
• Are current staging systems for cancer serving us well?
• Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy.
• Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
• Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique.
• FK506 and erectile function preservation in the cavernous nerve injury model: optimal dosing and timing.
• Five genetic variants associated with prostate cancer.
• Full thickness bladder flap for reconstruction of contracted vesical neck.
• Imaging low-risk prostate cancer.
• Localized prostate cancer is rarely a fatal disease.
• Low risk prostate cancer in men under age 65: The case for definitive treatment.
• Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent.
• Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram.
• Prognostic significance of location of positive margins in radical prostatectomy specimens.
• Surgeon Experience is Strongly Associated With Biochemical Recurrence After Radical Prostatectomy for All Preoperative Risk Categories.
• The functional and structural consequences of cavernous nerve injury are ameliorated by sildenafil citrate.
• The natural history of noncastrate metastatic prostate cancer after radical prostatectomy.
• The surgical learning curve for prostate cancer control after radical prostatectomy.
• The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis.
• Urology: a long history of innovation.